Genflow Seeks Investors for Novel SIRT6 DNA Repair Anti-Ageing Therapy
Great to see a startup willing to explicitly state they are treating ageing itself as a disease
Eric Leire
CEO of Genflow Biosciences and Executive Chairman of Immunethep
A wide range of leading positions in pharmaceutical and biotech companies, including Immunethep, DanDrit/Enochian, Pfizer, Schering Plough, Pharmacia and BioStrategies.
Also a Non Executive Director at Novicol International Holding Inc
Early academic experience includes Research Associate at the Harvard AIDS Institute.
Visit website: https://genflowbio.com/leadership/#eric
See also: 
Genflow Biosciences
- Developing medicines that potentially halt, slow or reverse the aging process
Details last updated 13-Jul-2020
Eric Leire is also referenced in the following:
Eric Leire Blog Posts
16-Jul-2020
Eric Leire News
Genflow Biosciences secures £715,000 funding for gene therapy research
ACCESSWIRE - 04-Apr-2024
Company aims to target age-related diseases and liver disease NASH
Read more...Genflow's sirtuin gene therapy can make old liver young again
Longevity Technology - 29-Mar-2022
Currently exploring the SIRT6 potential with University of Rochester’s Aging Research Center
Read more...Genflow IPO listing: the first longevity firm to debut on London Stock Exchange
Longevity Technology - 10-Jan-2022
Seeking funds to develop gene therapies that target ageing in humans and dogs
Read more...SIRT6 variant plays a major role in preventing the aging process
Longevity Technology - 17-Aug-2021
Novel gene therapies to prevent the accelerated aging process
Read more...
